Price
CHART BY
Frequently asked questions
What is GeoVax Labs's market capitalization?
The market capitalization of GeoVax Labs is $3.68M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for GeoVax Labs?
GeoVax Labs's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$13.93. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for GeoVax Labs's stock?
Currently, 1 analysts cover GeoVax Labs's stock, with a consensus target price of $10.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for GeoVax Labs?
GeoVax Labs's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$20.47M. EBITDA measures the company's overall financial performance.
What is the free cash flow of GeoVax Labs?
GeoVax Labs has a free cash flow of -$18.37M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does GeoVax Labs have, and what sector and industry does it belong to?
GeoVax Labs employs approximately 19 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of GeoVax Labs's shares?
The free float of GeoVax Labs is 9.09M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.68M
- EPS (TTM)
- -$13.93
- Free Float
- 9.09M
- EBITDA (TTM)
- -$20.47M
- Free Cashflow (TTM)
- -$18.37M
Pricing
- 52W span
- $0.40$17.50
Analyst Ratings
The price target is $10.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola-Zaire, Ebola-Sudan, Lassa, Marburg, Zika virus and malaria. The company was founded in June 1988 and is headquartered in Smyrna, GA.
- Employees
- 19
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- GOVX
Fundamentals & EOD data from FactSet